RPG Life Sciences Limited — Earnings Release 2023

Feb 1, 2023

==> picture [451 x 61] intentionally omitted <==

==> picture [451 x 28] intentionally omitted <==

February 01, 2023

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051

BSE Limited Corporate Relationship Department Floor 25, P.J. Towers, Dalal Street, Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of Press Release with respect to Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022.

Kindly take the above on record.

Thanking you,

Yours Sincerely, For RPG Life Sciences Limited Rajesh Shirambekar Head – Legal & Company Secretary

==> picture [67 x 66] intentionally omitted <==

Encl.: as above

==> picture [453 x 47] intentionally omitted <==

==> picture [156 x 61] intentionally omitted <==

Q3 FY23 Revenue from operations grew by 13% and PBT grew by 25% Y-o-Y. 9M FY23 Revenue from operations grew by 17% and PBT grew by 25% with EBITDA margin expanding from 22.2% to 22.8% Y-o-Y.

Mumbai, 1 February, 2023 : RPG Life Sciences Limited has announced its financial results for the third quarter and nine months ended December 31, 2022.

		Y-o-Y Revenue from operationsY-o-Y PBT
Q3	FY23 Highlights	Rs 130.60 crores – up from Rs 115.58 crores Rs 25.74 crores – up from Rs 20.62 crores
9M	FY23 Highlights	Rs 394.32 crores – up from Rs 336.36 crores Rs 77.87 crores – up from Rs 62.24 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 25% Y-o-Y for Q3 FY23, maintaining the upward trajectory in EBITDA margins, which improved from 21.4% to 22.8% Y-o-Y. Revenue from operations at Rs 130.60 crores registered a growth of 13% Y-o-Y for Q3 FY23. For 9M FY23 too, the company posted a jump in PBT by 25% Y-o-Y and recorded EBITDA margin expansion from 22.2% to 22.8% Y-o-Y. Revenue from operations at Rs 394.32 crores registered a growth of 17% Y-o-Y for 9M FY23.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q3 FY23, Company maintained its upward trajectory of overall robust performance by posting yet another strong results despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by healthy 13% and 25% respectively Y-o-Y. EBITDA margin grew from 21.4% to 22.8% Y-o-Y.

Domestic Formulations business, the biggest contributor to company business, recorded robust growth both in value and volumes - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has also shown robust growth while API business has also picked up growth momentum. Our relentless focus on achieving cost efficiencies in our operations, eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India’s fastest growing business groups with a turnover of US$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

==> picture [67 x 67] intentionally omitted <==

Media Contact: Svati Maddur Senior Manager – Corporate Brand and Group Communications +91 9920887227 | svati@rpg.in

==> picture [130 x 26] intentionally omitted <==